News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cystic Fibrosis Foundation Therapeutics, Inc. And Predix Pharmaceuticals Announce Drug Discovery Collaboration To Treat Cystic Fibrosis



10/19/2005 5:13:01 PM

WOBURN, Mass. & BETHESDA, Md.--(BUSINESS WIRE)--March 16, 2005--Predix Pharmaceuticals Holdings Inc., a drug discovery and development company, and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced today that they have signed a research, development and commercialization agreement. The company will receive up to $12.5 million in milestone-driven funds over the next three years through a therapeutics development award from CFFT for two programs. Cystic fibrosis (CF) is a genetic disease affecting approximately 30,000 children and adults in the United States. A defective gene causes the body to produce an abnormally thick, sticky mucus that clogs the lungs, leading to life-threatening lung infections, and obstructs the pancreas, causing difficulty absorbing food. The median life expectancy has improved from early childhood to the mid-30s today, but many individuals battle lung disease for years.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES